MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Buys $100,500.00 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 75,000 shares of MAIA Biotechnology stock in a transaction dated Monday, June 1st. The stock was bought at an average cost of $1.34 per share, with a total value of $100,500.00. Following the completion of the purchase, the director owned 1,519,178 shares in the company, valued at approximately $2,035,698.52. This trade represents a 5.19% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

MAIA Biotechnology Price Performance

NYSEAMERICAN MAIA opened at $1.30 on Tuesday. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $3.19. The firm has a market capitalization of $79.04 million, a PE ratio of -1.94 and a beta of 0.23. The company’s 50 day simple moving average is $1.32 and its 200 day simple moving average is $1.52.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. Sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -0.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Centric Wealth Management boosted its stake in MAIA Biotechnology by 2.0% during the fourth quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after buying an additional 11,500 shares in the last quarter. Geode Capital Management LLC raised its position in MAIA Biotechnology by 9.5% in the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after acquiring an additional 25,684 shares in the last quarter. Corsair Capital Management L.P. acquired a new stake in MAIA Biotechnology in the 1st quarter valued at about $140,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology during the 4th quarter valued at about $120,000. Finally, Ritholtz Wealth Management bought a new position in shares of MAIA Biotechnology during the 4th quarter valued at about $35,000. Institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.